We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $114B Turnover 39.14%
1-Year Est. Return 35.47%
 

Marshall Wace is a British firm that runs long/short hedge funds. Its strategies combine computer-driven and traditional company analysis, applied worldwide and mostly to long/short equity. Paul Marshall, formerly head of European equities at Mercury Asset Management, and Ian Wace, formerly head of equities trading at Deutsche Bank, founded it in 1997. In 2002 it launched TOPS, a system that gathers investment ideas from equity professionals and uses algorithms to turn them into stock portfolios. In 2015 Marshall Wace formed a long-term partnership with KKR, a private equity and credit investor that took an ownership interest in the firm.

This Fund
S&P 500
This Quarter Est. Return
-12.49%
1 Year Est. Return
+35.47%
3 Year Est. Return
+152.7%
5 Year Est. Return
+193.18%
10 Year Est. Return
+740.37%
AUM
$48.6B
AUM Growth
-$4.2B
Cap. Flow
+$2.77B
Cap. Flow %
5.69%
Top 10 Hldgs %
10.29%
Holding
4,108
New
835
Increased
963
Reduced
740
Closed
743
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$340M
2
BAC icon
Bank of America
BAC
+$302M
3
CI icon
Cigna
CI
+$294M
4
TSM icon
TSMC
TSM
+$275M
5
UNP icon
Union Pacific
UNP
+$256M

Top Sells

Rank Stock Value
1
VZ icon
Verizon
VZ
+$426M
2
SPGI icon
S&P Global
SPGI
+$413M
3
BKNG icon
Booking.com
BKNG
+$264M
4
CMCSA icon
Comcast
CMCSA
+$256M
5
TFX icon
Teleflex
TFX
+$241M

Sector Composition

Rank Sector Weight
1 Healthcare 17.67%
2 Financials 16.99%
3 Technology 16.42%
4 Miscellaneous 11.36%
5 Consumer Discretionary 9.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AAPL icon
1
Apple
AAPL
$4.98T
$724M 1.49%
5,295,451
+32,704
+0.6% +$4.95M
2014 Q1
33 quarters
MSFT icon
2
Microsoft
MSFT
$3.6T
$638M 1.31%
2,485,076
+30,195
+1% +$8.2M
2017 Q4
18 quarters
AMZN icon
3
Amazon
AMZN
$2.67T
$565M 1.16%
5,318,307
+983,327
+23% +$123M
2013 Q2
36 quarters
MRK icon
4
Merck
MRK
$330B
$529M 1.09%
5,801,745
-983,823
-14% -$87.2M
2021 Q3
3 quarters
UNH icon
5
UnitedHealth
UNH
$305B
$519M 1.07%
1,009,871
-334,311
-25% -$168M
2020 Q1
9 quarters
JNJ icon
6
Johnson & Johnson
JNJ
$651B
$514M 1.06%
2,893,320
+930,025
+47% +$166M
2021 Q1
5 quarters
BSX icon
7
Boston Scientific
BSX
$60.8B
$391M 0.8%
10,479,137
+938,755
+10% +$38.2M
2016 Q1
25 quarters
TMO icon
8
Thermo Fisher Scientific
TMO
$248B
$390M 0.8%
718,514
+398,226
+124% +$219M
2018 Q4
14 quarters
LLY icon
9
Eli Lilly
LLY
$1.2T
$367M 0.76%
+1,133,393
New +$340M
2022 Q2
0 quarters
KO icon
10
Coca-Cola
KO
$417B
$366M 0.75%
5,814,967
+2,943,567
+103% +$187M
2020 Q1
9 quarters
AVGO icon
11
Broadcom
AVGO
$1.45T
$346M 0.71%
7,131,790
-1,734,010
-20% -$97.3M
2016 Q1
25 quarters
CI icon
12
Cigna
CI
$71.4B
$340M 0.7%
1,289,848
+1,141,865
+772% +$294M
2021 Q2
4 quarters
PFE icon
13
Pfizer
PFE
$156B
$325M 0.67%
6,203,088
+3,836,099
+162% +$195M
2021 Q1
5 quarters
BAC icon
14
Bank of America
BAC
$325B
$318M 0.65%
10,213,335
+8,374,126
+455% +$302M
2020 Q4
6 quarters
HUM icon
15
Humana
HUM
$46.8B
$309M 0.63%
659,378
+110,704
+20% +$49.3M
2021 Q4
2 quarters
TSLA icon
16
Tesla
TSLA
$1.37T
$301M 0.62%
1,342,848
+342,543
+34% +$93.5M
2020 Q3
7 quarters
WFC icon
17
Wells Fargo
WFC
$236B
$297M 0.61%
7,583,259
-4,904,659
-39% -$215M
2019 Q4
10 quarters
QQQ icon
18
CALL
Invesco QQQ Trust
QQQ
$418B
$289M 0.59%
1,030,400
+938,100
+1,016% +$291M
2021 Q4
2 quarters
BHVN icon
19
DELISTED
Biohaven Pharmaceutical Holding
BHVN
$281M 0.58%
1,928,624
-472,660
-20% -$60.4M
2019 Q1
13 quarters
ABNB icon
20
Airbnb
ABNB
$100B
$281M 0.58%
3,152,626
+431,790
+16% +$56.2M
2020 Q4
6 quarters
UNP icon
21
Union Pacific
UNP
$171B
$280M 0.58%
1,315,137
+1,127,124
+599% +$256M
2020 Q4
6 quarters
CHTR icon
22
Charter Communications
CHTR
$14.7B
$276M 0.57%
589,588
+480,441
+440% +$234M
2018 Q3
15 quarters
TSM icon
23
TSMC
TSM
$1.65T
$268M 0.55%
3,283,059
+2,970,917
+952% +$275M
2021 Q3
3 quarters
SPY icon
24
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$732B
$262M 0.54%
695,800
+675,600
+3,345% +$277M
2022 Q1
1 quarter
CSX icon
25
CSX
CSX
$90.5B
$251M 0.52%
8,643,657
+5,143,741
+147% +$168M
2021 Q4
2 quarters

Similar funds

Marshall Wace's Q2 2022 Portfolio in Review

As of Q2 2022, Marshall Wace held 4,108 positions worth $48.6B, down 8% from $52.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.77B of net new capital in Q2 2022, opening 835 new positions and adding to 963 existing holdings. Its largest new stake was Eli Lilly: 1,133,393 shares worth $367M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Verizon, an estimated $426M trimmed.

  • Marshall Wace's largest Q2 2022 buy was Eli Lilly: 1,133,393 shares worth $367M.
  • Marshall Wace added most to Bank of America in Q2 2022, an estimated $302M increase.
  • Marshall Wace's biggest Q2 2022 reduction was Verizon, cutting an estimated $426M.
  • Marshall Wace fully exited Teleflex in Q2 2022, selling an estimated $241M.
  • Marshall Wace's ten largest holdings make up 10% of its $48.6B portfolio in Q2 2022.
  • Marshall Wace opened 835 new positions and closed 743 in Q2 2022.
  • Marshall Wace's portfolio value fell 8% quarter-over-quarter to $48.6B.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.